Posting Date: May 20, 2021

Closing Date: May 30, 2021 11:30 a.m. ET

Reference Number: 21-037120

To: NCI Bid Board

From: Tanya Proctor
NCI CCR P-ARC
Tanya.proctor@nih.gov

Subject: NCI Bid Board Posting – 4D-Nucleofector Core Unit

The Center for Cancer Research (CCR) is the largest division of the National Cancer Institute (NCI) intramural research program. The mission of CCR is to improve the lives of all cancer patients by solving important, challenging and neglected problems in cancer research and patient care through a world-leading basic, translational and clinical research and patient care program. An institutional focus on high-risk and long-term projects, unmet needs, and pursuit of unexplored ideas. Research to eliminate cancer health disparities. Leadership and coordination of national disease networks and development of technology resources for the cancer community. Partnerships with academic institutions, commercial entities and patient advocacy groups.

The National Cancer Institute plans to purchase 4D-Nucleofector Core Unit and 4D-Nucleofector X Unit from Lonza. This is not a request for competitive quotation. However, if any interested party believes it can meet the attached requirements, it may submit a statement of capabilities. The capability statement must be in writing and must contain information and material in sufficient detail to allow NCI to determine is the party can fully meet this requirement. The capability statement must be received in the contracting office by 11:30 AM on May 30, 2021 ET. A determination by the Government not to compete this requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement.

Sole Source Justification:

The Lonza 4D nucleofector will allow us to quickly produce CAR T cells using primary patient cells, which may have high transfection efficiency, high cell viability after transfection, low non-specific T cell tonic signaling, low exhaustion and improved function/stemness of T cells, without the need to produce lentivirus to avoid batch-to-batch variations of lentivirus titers and quality. We may also use this equipment to design new non-viral delivery (e.g., RNA) of CAR T or NK cells in the future. There is no equipment budget in any of our three CAR clinical development projects.

Attached Documents:
SF18
Statement of Work
FAR Clause 52.213-4 Simplified Acquisitions Terms and Conditions (JAN 2014) is applicable and available in full text upon request